Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Por Johnson, Peter W. M.
Publicado no Hematology Am Soc Hematol Educ Program (2016)

Bone marrow transplants : New indications exploit the immune effects of the transplanted cells

Por Johnson, Peter W M, Orchard, Kim
Publicado em 2002

Options for first line therapy of Hodgkin lymphoma

Por Longley, Jemma, Johnson, Peter W.M.
Publicado no Hematol Oncol (2019)

(18)F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?

Por Barrington, Sally F., Johnson, Peter W.M.
Publicado no J Nucl Med (2017)

Anti-CD20 monoclonal antibodies: historical and future perspectives

Por Lim, Sean H., Beers, Stephen A., French, Ruth R., Johnson, Peter W.M., Glennie, Martin J., Cragg, Mark S.
Publicado em 2010

Thioflavin S (NSC71948) Interferes with Bcl-2-Associated Athanogene (BAG-1)-Mediated Protein-Protein Interactions

Por Sharp, Adam, Crabb, Simon J., Johnson, Peter W. M., Hague, Angela, Cutress, Ramsey, Townsend, Paul A., Ganesan, A., Packham, Graham
Publicado em 2009

Antibody–peptide–MHC fusion conjugates target non-cognate T cells to kill tumour cells

Por King, Ben C., Hamblin, Angela D., Savage, Philip M., Douglas, Leon R., Hansen, Ted H., French, Ruth R., Johnson, Peter W. M., Glennie, Martin J.
Publicado em 2013

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma

Por Illidge, Tim M., Phillips, Elizabeth H., Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter W. M., Culligan, Dominic J., Popova, Bilyana, Clifton-Hadley, Laura, McMillan, Andrew, Hoskin, Peter, Barrington, Sally F., Radford, John
Publicado no Blood Adv (2020)

RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial

Por Lim, Sean H., Linton, Kim M., Collins, Graham P., Dhondt, Joke, Caddy, Joshua, Rossiter, Liz, Vadher, Karan, Fines, Keira, Rogers, Laura E., Fernando, Diana, Stanton, Louise, Davies, Andrew J., Johnson, Peter W. M., Griffiths, Gareth
Publicado no Trials (2018)

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

Por Cummin, Thomas E. C., Cox, Kerry L., Murray, Tom D., Turaj, Anna H., Dunning, Lisa, English, Vikki L., Fell, Rachel, Packham, Graham, Ma, Yan, Powell, Ben, Johnson, Peter W. M., Cragg, Mark S., Carter, Matthew J.
Publicado no Blood Adv (2020)

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lym...

Por Rule, Simon, Smith, Paul, Johnson, Peter W.M., Bolam, Simon, Follows, George, Gambell, Joanne, Hillmen, Peter, Jack, Andrew, Johnson, Stephen, Kirkwood, Amy A, Kruger, Anton, Pocock, Christopher, Seymour, John F., Toncheva, Milena, Walewski, Jan, Linch, David
Publicado no Haematologica (2016)

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

Por Anderson, Richard A, Remedios, Rachel, Kirkwood, Amy A, Patrick, Pip, Stevens, Linsey, Clifton-Hadley, Laura, Roberts, Tom, Hatton, Chris, Kalakonda, Nagesh, Milligan, Don W, McKay, Pam, Rowntree, Clare, Scott, Fiona M, Johnson, Peter W M
Publicado no Lancet Oncol (2018)

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking

Por Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.
Publicado no Sci Rep (2018)

Primary Mediastinal B-Cell Lymphoma : High Frequency of BCL-6 Mutations and Consistent Expression of the Transcription Factors OCT-2, BOB.1, and PU.1 in the Absence of Immunoglobul...

Por Pileri, Stefano A., Gaidano, Gianluca, Zinzani, Pier Luigi, Falini, Brunangelo, Gaulard, Philippe, Zucca, Emanuele, Pieri, Federica, Berra, Eva, Sabattini, Elena, Ascani, Stefano, Piccioli, Milena, Johnson, Peter W. M., Giardini, Roberto, Pescarmona, Edoardo, Novero, Domenico, Piccaluga, Pier Paolo, Marafioti, Teresa, Alonso, Miguel A., Cavalli, Franco
Publicado em 2003

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Por Yap, Timothy A., Winter, Jane N., Giulino-Roth, Lisa, Longley, Jemma, Lopez, Juanita, Michot, Jean-Marie, Leonard, John P., Ribrag, Vincent, McCabe, Michael T., Creasy, Caretha L., Stern, Melissa, Pene Dumitrescu, Teodora, Wang, Xiaowei, Frey, Steve, Carver, Jennifer, Horner, Thierry, Oh, Choon, Khaled, Ahmed, Dhar, Arindam, Johnson, Peter W.M.
Publicado no Clin Cancer Res (2019)

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

Por White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane, Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M., Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A., Glennie, Martin J.
Publicado no Cancer Cell (2015)

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Por Sha, Chulin, Barrans, Sharon, Cucco, Francesco, Bentley, Michael A., Care, Matthew A., Cummin, Thomas, Kennedy, Hannah, Thompson, Joe S., Uddin, Rahman, Worrillow, Lisa, Chalkley, Rebecca, van Hoppe, Moniek, Ahmed, Sophia, Maishman, Tom, Caddy, Josh, Schuh, Anna, Mamot, Christoph, Burton, Catherine, Tooze, Reuben, Davies, Andrew, Du, Ming-Qing, Johnson, Peter W.M., Westhead, David R.
Publicado no J Clin Oncol (2019)

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

Por Cucco, Francesco, Barrans, Sharon, Sha, Chulin, Clipson, Alexandra, Crouch, Simon, Dobson, Rachel, Chen, Zi, Thompson, Joe Sneath, Care, Matthew A., Cummin, Thomas, Caddy, Josh, Liu, Hongxiang, Robinson, Anne, Schuh, Anna, Fitzgibbon, Jude, Painter, Daniel, Smith, Alexandra, Roman, Eve, Tooze, Reuben, Burton, Catherine, Davies, Andrew J., Westhead, David R., Johnson, Peter W. M., Du, Ming-Qing
Publicado no Leukemia (2019)

The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit

Por Clipson, Alexandra, Barrans, Sharon, Zeng, Naiyan, Crouch, Simon, Grigoropoulos, Nicholas F, Liu, Hongxiang, Kocialkowski, Sylvia, Wang, Ming, Huang, Yuanxue, Worrillow, Lisa, Goodlad, John, Buxton, Jenny, Neat, Michael, Fields, Paul, Wilkins, Bridget, Grant, John W, Wright, Penny, EI‐Daly, Hesham, Follows, George A, Roman, Eve, Watkins, A James, Johnson, Peter W M, Jack, Andrew, Du, Ming‐Qing
Publicado no J Pathol Clin Res (2015)

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Por Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M
Publicado no Lancet Oncol (2019)